13 Mar 2006 - PamGene International BV and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica NV have announced significant progress in their kinase profiling collaboration. After extensive evaluation, PamGene's microarray-based biochemical kinase activity profiling and cellular inhibition assays will be further implemented in J&JPRD's research programs.
The evaluation program involved kinase inhibitor characterization on a panel of recombinant kinases. Additionally, a number of reference and J&JPRD proprietary kinase inhibitors were characterized in whole cell-based experiments. Kinase activity was measured by phosphorylation profiles (fingerprints) obtained from the kinetic readout from lysates of compound-treated cells.
 |
www.bionity.com/news/e/52990 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/52990 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |